TC Biopharm (Holdings) (TCBP) Company Overview

EDINBURGH, Scotland , Feb. 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will change its ratio of its American Depositary Shares ("ADSs") to ordinary shares from one (1) ADS representing two hundred (200) ordinary shares to one ADS representing four thousand (4,000) ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on February 10, 2025, U.S. Eastern Time.

EDINBURGH, Scotland , Jan. 15, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as "Bird Flu." The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study.

EDINBURGH, Scotland , Jan. 6, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its American Depository Shares (ADSs) has continued trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol 'TCBP'. There has been no halt in trading and shares are expected to continue trading unabated.

EDINBURGH, Scotland , Dec. 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T-cell therapies for cancer and other indications, today announced it has advanced negotiations with both of its previously aforementioned acquisition candidates. This past spring TCBP announced the execution of non-binding letters of intent as part of its M&A strategy aimed at expanding its therapeutic platform.

EDINBURGH, Scotland , Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company.

EDINBURGH, Scotland , Dec. 20, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced 3 patients have now completed the full-dose regimen in the ACHIEVE Phase 2b trial in the UK with no drug-related Adverse Events seen in any of the restart patients. The ACHIEVE UK clinical trial is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease.

EDINBURGH, Scotland , Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting of shareholders ("GM") at 2:00 p.m.

EDINBURGH, Scotland , Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has been awarded non-dilutive funding of $250,000 from the G-Rex® Grant Program.  The G-Rex® Grant Program, launched by ScaleReady alongside Wilson Wolf Manufacturing and the Bio-Techne Corporation, is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing.

EDINBURGH, Scotland , Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024. "The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceutical company," said Bryan Kobel, CEO of TC BioPharm.